Artritis psoriásica

  1. Villalobos Sánchez, L. 1
  2. Guillén Astete, C. 1
  3. Garrote Corral, S. 1
  4. Terán Tinedo, M.A. 1
  5. Vázquez Díaz, M. 1
  1. 1 Servicio de Reumatología, Hospital Universitario Ramón y Cajal, Madrid, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Serie: 13

Número: 29

Páginas: 1623-1634

Tipo: Artículo

DOI: 10.1016/J.MED.2021.03.020 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

La artritis psoriásica (Aps) es una artropatía inflamatoria crónica que está asociada con la presencia de psoriasis cutánea y factor reumatoide (FR) usualmente negativo. El desarrollo de esta enfermedad depende de factores genéticos predisponentes, condicionantes inmunológicos que perpetúan el ciclo inflamatorio local y la participación de las vías Th1/Th17, así como de las interleuquinas IL-9, IL-12/23 e IL-17. Si bien una parte de la génesis de la Aps se ha explicado mediante estudios de asociación, el conocimiento de los mecanismos que la hacen posible es actualmente incompleto. No hay pruebas específicas para el diagnóstico. Nos basamos en los criterios de clasificación CASPAR y en el apoyo de técnicas de imagen. En los últimos años ha habido un gran avance en el tratamiento inmunosupresor de la Aps, surgiendo nuevos tratamientos contra diferentes dianas.

Referencias bibliográficas

  • Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. The Lancet. 2018;391(10136):2285-94.
  • Romero Pérez A, Queiro R, Seoane Mato D, Graell E, Chamizo E, Chaves Chaparro L, Proyecto EPISER2016 Working Group. Higher prevalence of psoriatic arthritis in the adult population in Spain? A population based cross sectional study. PLoS One. 2020;15(6):e0234556.
  • Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis. 1973;32(3):181-201.
  • Zhang XJ, He PP, Wang ZX, Zhang J, Li YB, Wang HY, Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome wide scan in Chinese hans. J Invest Dermatol. 2002;119(6):1361-6.
  • O’Rielly DD, Rahman P. Genetics of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2014;28(5):673-85.
  • Lories RJ, McInnes IB. Primed for inflammation: enthesis resident T cells. Nat Med. 2012;18(7):1018-9.
  • Chandran V, Bull SB, Pellett FJ, Ayearst R, Pollock RA, Gladman DD. Killer cell immunoglobulin like receptor gene polymorphisms and susceptibility to psoriatic arthritis. Rheumatol Oxf Engl. 2014;53(2):233-9.
  • Bowes J, Ashcroft J, Dand N, Jalali Najafabadi F, Bellou E, Ho P, Cross phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. Ann Rheum Dis. 2017;76(10):1774-9.
  • Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2):530.
  • Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3): 379-90.
  • Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763-76.
  • Ciccia F, Guggino G, Ferrante A, Raimondo S, Bignone R, Rodolico V, Interleukin-9 overexpression and Th9 polarization characterize the inflamed gut, the synovial tissue, and the peripheral blood of patients with psoriatic arthritis. Arthritis Rheumatol Hoboken NJ. 2016;68(8): 1922-31.
  • Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-73.
  • Wright V, Moll JM. Psoriatic arthritis. Bull Rheum Dis. 1971;21(5): 627-32.
  • Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke W-H, Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387-94.
  • Feld J, Chandran V, Gladman DD. What is axial psoriatic arthritis? J Rheumatol. 2018;45(12):1611-3.
  • Bakewell C, Aydin SZ, Ranganath VK, Eder L, Kaeley GS. Imaging techniques: options for the diagnosis and monitoring of treatment of enthesitis in psoriatic arthritis. J Rheumatol. 2020;47(7):973-82.
  • Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP. Extended report: nail disease in psoriatic arthritis clinically important, potentially treatable and often overlooked. Rheumatology. 2004;43(6):790-4.
  • Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population based study. Arthritis Rheum. 2009;61(2):233-9.
  • Durrani K, Foster CS. Psoriatic uveitis: A distinct clinical entity? Am J Ophthalmol. 2005;139(1):106-11.
  • Fu Y, Lee C-H, Chi C-C. Association of psoriasis with inflammatory bowel disease: a systematic review and meta analysis. JAMA Dermatol. 2018;154(12):1417-23.
  • Torre Alonso JC, Carmona L, Moreno M, Galíndez E, Babío J, Zarco P, Identification and management of comorbidity in psoriatic arthritis: evidence and expert based recommendations from a multidisciplinary panel from Spain. Rheumatol Int. 2017;37(8):1239-48.
  • Eder L, Wu Y, Chandran V, Cook R, Gladman DD. Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann Rheum Dis. 2016;75(9):1680-6.
  • Ogdie A, Grewal SK, Noe MH, Shin DB, Takeshita J, Chiesa Fuxench ZC, Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population based study. J Invest Dermatol. 2018;138(4):760-7.
  • Zusman EZ, Howren AM, Park JYE, Dutz J, De Vera MA. Epidemiology of depression and anxiety in patients with psoriatic arthritis: A systematic review and meta analysis. Semin Arthritis Rheum. 2020;S0049017 220300202.
  • Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045.
  • Johnson SR. Autoantibodies in biological agent naive patients with psoriatic arthritis. Ann Rheum Dis. 2005;64(5):770-2.
  • Queiro R, Torre JC, González S, López Larrea C, Tinturé T, López Lagunas I. HLA antigens may influence the age of onset of psoriasis and psoriatic arthritis. J Rheumatol. 2003;30(3):505-7.
  • Siannis F. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis. 2006;65(4):478-81.
  • Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology. 2003;42(12):1460-8.
  • Sapundzhieva T, Karalilova R, Batalov A. Hand ultrasound patterns in rheumatoid and psoriatic arthritis: the role of ultrasound in the differential diagnosis. Rheumatol Int. 2020;40(6):837-48.
  • Wervers K, Luime JJ, Tchetverikov I, Gerards AH, Kok MR, Appels CWY, Comparison of disease activity measures in early psoriatic arthritis in usual care. Rheumatology. 2019;58(12):2251-9.
  • Coates LC, Nash P, Kvien TK, Gossec L, Mease PJ, Rasouliyan L, Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. Semin Arthritis Rheum. 2020;50(4):709-18.
  • Arumugam R, McHUGH NJ. Mortality and causes of death in psoriatic arthritis. J Rheumatol Suppl. 2012;89(0):32-5.
  • Coates LC, Moverley AR, McParland L, Brown S, Navarro Coy N, O’Dwyer JL, Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open label, rando mised controlled trial. The Lancet. 2015;386(10012):2489-98.
  • Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, EULAR recommendations for the manage-ment of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-12.
  • Schemoul J, Poulain C, Claudepierre P. Treatment strategies for psoriatic arthritis. Joint Bone Spine. 2018;85(5):537-44.
  • Behrens F, Finkenwirth C, Pavelka K, Štolfa J, Šipek Dolnicar A, Thaçi D, Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res. 2013;65(3):464-70.
  • Simons N, Degboé Y, Barnetche T, Cantagrel A, Ruyssen Witrand A, Constantin A. Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta analysis on articular, enthesitis, dactylitis, skin and functional outcomes. Clin Exp Rheumatol.2020;38(3):508-15.
Fuente de los datos: Dialnet